FRIENDSWOOD, Texas — November 3, 2025 — Leads & Copy — Castle Biosciences, Inc. (Nasdaq: CSTL) announced its Q3 2025 financial results, featuring $83 million in revenue.
Q3 non-dermatologic revenue increased by 67% over Q3 2024, and total test reports for DecisionDx®-Melanoma and TissueCypher® increased 36% over Q3 2024. The company is raising its full-year 2025 revenue guidance to $327-335 million from $310-320 million.
Castle Biosciences also announced the launch of AdvanceAD-Tx™, a test designed to guide systemic treatment decision-making in patients ages 12 and older with moderate-to-severe atopic dermatitis (AD).
Key highlights from the third quarter include:
- Revenues of $83.0 million
- 26,841 total test reports delivered
- Gross margin of 75% (Adjusted Gross Margin: 77%)
- Net cash provided by operations: $22.6 million
- Net loss of $0.5 million
- Adjusted EBITDA of $9.2 million
Camilla Zuckero, Investor Relations Contact, can be reached at czuckero@castlebiosciences.com or 281-906-3868. Allison Marshall is the Media Contact and can be reached at amarshall@castlebiosciences.com.
Source: Castle Biosciences
